Adam J. Horowitz

Adam J. Horowitz is a versatile associate in Goodwin’s Intellectual Property Litigation practice and a member of the firm’s Cannabis practice. He represents pharmaceutical, biotech, technology, and cannabis industry clients in complex patent, licensing, trade secret, and commercial disputes in federal courts, arbitrations, and administrative proceedings. Adam’s extensive experience in atypical litigation matters allows him to quickly adjust case strategy as new facts emerge. He represents both branded and generics pharmaceutical companies, granting him full-spectrum insight into the likely litigation strategies to be used by opposing parties. Further, Adam has represented both large companies and startups, taking care to understand each client’s specific goals and needs, whether in bet-the-company litigation or more routine actions. Adam regularly uses his understanding of the industry to advise companies operating in highly regulated industries on litigation risk, licensing, and compliance strategies in order to best protect his clients’ intellectual property and avoid unfavorable government action. 

• Secured a victory through binding AAA arbitration on behalf of gene-editing client, successfully defending client’s right to develop critical, cutting-edge therapy
• Represent branded pharmaceutical company in both offensive and defensive patent litigation, including at trial in federal district court
• Successfully defeated motion for temporary enforcement order before the ITC and ultimately secured final opinion finding noninfringement on basis of invalidity
• Litigated Hatch-Waxman action on behalf of generics company involving method of treatment and formulation patents and secured favorable settlement
• Secured favorable settlement in Lanham Act and unfair competition litigation between pharmaceutical companies
• Obtained favorable final award, including order piercing the corporate veil, through international arbitration regarding against company violating licensing agreement and misappropriating trade secrets
• Supported patent litigation and ITC-related matters involving electronics and semiconductor technologies, including subpoena responses and licensing disputes
• Assisted in trade secret and commercial disputes involving biotechnology and life sciences companies, including matters relating to inhaled therapeutics and related IP portfolios
• Advised and represented cannabis operators in securing cultivation, manufacturing, and dispensary licenses before the New Jersey Cannabis Regulatory Commission and the New York Office of Cannabis Management
• Counseled hemp and cannabis businesses on multistate regulatory compliance, licensing strategy, and operational risk in highly regulated markets
• Counsel publicly traded companies on the potential risks associated with entering the consumable hemp market
• Provide regulatory guidance in connection to mergers of multistate cannabis operators
• Negotiated licensing, management services, and commercial agreements for cannabis and emerging-growth companies
• Prepared compliance frameworks and best-practice guidance for national marketing and consumer brands operating in regulated cannabis environments
• Represented executives and companies in arbitration proceedings and employment-related disputes, including matters involving non-compete and non-solicitation agreements
• Secured favorable results on dispositive motions in federal and state court proceedings

Prior to joining Goodwin in 2022, Adam worked as an associate in Cole Schotz, P.C. and Mound Cotton Collan & Green Grass, LLP’s New York offices.

• Co-Author, “DEA Inviting Only Marijuana Opponents To Participate In Rescheduling Hearing Is Actually An ‘Encouraging Sign’ For Supporters (Op-Ed),” Marijuana Moment, July 1, 2026
• Co-Author, “A Legal Tug of War on Hemp-Derived Cannabinoid Regulations,” Cannabis Business Times, October 22, 2024
• Co-Author, “Moving the Goalposts: State Regulation of Hemp-Derived Cannabinoids,” Cannabis Business Times, August 2, 2024
• Co-Author, “Hemp-Derived Delta-9 THC: What’s Next?” Cannabis Business Times, February 27, 2024
• Co-Author, “Interstate Cannabis Commerce May Be In Reach, With Caveats,” Law360, April 20, 2023
• Author, “Cannabis Marketing Proposed Regulations in New York & Neighboring States,” Bloomberg Law, January 27, 2023
• Author, “Microbusinesses: An Opportunity for Cities and Small Businesses,” Marijuana Venture Magazine, November 11, 2021
• Author, “How Bans on Cannabis Businesses May Impact Entrepreneurs,” Marijuana Venture Magazine, October 19, 2021
• Author, “New York and New Jersey: No vertical integration,” Marijuana Venture Magazine, June 9, 2021